CXCL9 and myeloid sarcoma: IL-8 [23], [24], IP-10 [25], MCP-1 [26], [27], MIP-1α [28], and MIG [29] levels were previously found to be differentially expressed in sera from patients with IFNβ treated MS as compared to untreated MS patients.